PubMed
Phase Ib dose-escalation study of the hypoxia-modifier Myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors
Schneider et al., 2021
GLP-1 & MetabolicResearch OnlyD
ITPP
Myo-inositol trispyrophosphate
Experimental oxygen-delivery/metabolic performance compound tracked in research circles.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 3
- Research grade
- D
- Experience
- 99
- Activity
- 79
Overall check-ins
Trackers & reports
Overview
About ITPP
Experimental oxygen-delivery/metabolic performance compound tracked in research circles.
- Category
- GLP-1 & Metabolic
- Regulatory status
- Research Only
- Also known as
- Myo-inositol trispyrophosphate
- Self-reports
- 21
Community
What 21 users report
21 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 97% · Mixed 3% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Recovery
140
Energy
140
Self-reported dose per injection
Median bucket: 2+ mg · Most common: 2+ mg
Reports span 1 to ≥ 2 mg (open-ended top bucket)
1–2 mg
41
2+ mg
99
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 90% said they felt similar to their last entry, 10% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 163 days · Based on 20 repeat reporters
Research
Cited research (2)
Source
ClinicalTrials.gov
Effects of OXY111A (Myo-inositol trispyrophosphate) in Hepato-Pancreato-Biliary Neoplasms (NCT02528526)
ClinicalTrials.gov, 2015
Tools
Explore more
Explore
More ways to learn about ITPP from observational PeptIQ data.
Related peptides
Help
Frequently asked
What do PeptIQ users report about ITPP?
This page summarizes 21 anonymized self-reports from PeptIQ users who track ITPP, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for ITPP?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for ITPP?
2 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is ITPP safe to use?
This wiki does not assess safety or recommend use. ITPP is listed as Research Only. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of ITPP?
Research, primarily in animal models, suggests ITPP may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.
SourceWhat is the legal status of ITPP?
ITPP is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified ITPP as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.
SourceWhat are the known or theoretical side effects and risks of ITPP?
The safety and effectiveness of ITPP have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.
SourceWhat is the current state of research on ITPP?
While there are over 200 published studies on ITPP, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.
Source